Effect and Mechanism of Chinese Patent Medicine Xinmaitong on Endothelial Function and Injury Repairment in Hypertension Disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000003070

Enrollment

Unknown

Registered

2020-03-01

Start date

2020-04-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiovascular disease

Interventions

control group:regular treatment

healthy control group:no intervention

experimental group:regular treatment combined with Xinmaitong

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Essential hypertension.

Exclusion criteria

Exclusion criteria: 1. Diabetes; 2. Coronary heart disease; 3. Nausea tumor; 4. Infectious disease.

Design outcomes

Primary

Measure	Time frame
endothelial function;blood pressure;	—

Countries

China

Contacts

Public ContactBin Zhang

Jiangmen Central Hospital

docbinzhang@163.com+86 15307501656

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026